Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1997 1
2001 1
2005 1
2012 1
2015 1
2016 1
2017 2
2018 2
2020 2
2021 2
2022 2
2023 2
2024 1
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

15 results

Results by year

Filters applied: . Clear all
Page 1
Occupational risk of nano-biomaterials: Assessment of nano-enabled magnetite contrast agent using the BIORIMA Decision Support System.
Cazzagon V, Giubilato E, Pizzol L, Ravagli C, Doumett S, Baldi G, Blosi M, Brunelli A, Fito C, Huertas F, Marcomini A, Semenzin E, Zabeo A, Zanoni I, Hristozov D. Cazzagon V, et al. Among authors: fito c. NanoImpact. 2022 Jan;25:100373. doi: 10.1016/j.impact.2021.100373. Epub 2021 Dec 10. NanoImpact. 2022. PMID: 35559879 Free article.
Occupational exposure to nanomaterials and biomarkers in exhaled air and urine: Insights from the NanoExplore international cohort.
Hemmendinger M, Squillacioti G, Charreau T, Garzaro G, Ghelli F, Bono R, Sauvain JJ, Suarez G, Hopf NB, Wild P, Progiou A, Fito C, Bergamaschi E, Guseva Canu I. Hemmendinger M, et al. Among authors: fito c. Environ Int. 2023 Sep;179:108157. doi: 10.1016/j.envint.2023.108157. Epub 2023 Aug 18. Environ Int. 2023. PMID: 37625222 Free article.
Real-world apremilast use in biologic-naïve psoriatic arthritis patients. Data from Spanish clinical practice.
Gratacós-Masmitja J, Beltrán Catalán E, Álvarez Vega JL, Urruticoechea-Arana A, Fito C, Maceiras F, Belzunegui Otano JM, Fernández Melón J, Chamizo Carmona E, Abad Hernández MÁ, Ros Vilamajó I, Castro Oreiro S, Pascual Alfonso E, Torre Alonso JC; PREVAIL team. Gratacós-Masmitja J, et al. Among authors: fito c. Reumatol Clin (Engl Ed). 2024 Jan;20(1):24-31. doi: 10.1016/j.reumae.2023.09.004. Reumatol Clin (Engl Ed). 2024. PMID: 38233009 Free article.
Effectiveness of ustekinumab in patients with psoriatic arthritis in a real-world, multicenter study.
Azuaga AB, Frade-Sosa B, Laiz A, Estrada P, Prior-Español A, Horcada L, Polino L, Moreno M, Moragues C, Urruticoechea-Arana A, Sellas A, Tandaipan JL, Torrente-Segarra V, Garcia-Miguel J, Ros I, Ordoñez S, Moya P, Reina D, Mateo-Soria L, Fito C, Beltrán E, Pujol M, Cuervo AM, Cañete JD, Ramírez J; ESPOCAT group. Azuaga AB, et al. Among authors: fito c. Clin Rheumatol. 2020 Oct;39(10):2963-2971. doi: 10.1007/s10067-020-05057-9. Epub 2020 Apr 13. Clin Rheumatol. 2020. PMID: 32285259
Abatacept in patients with rheumatoid arthritis and interstitial lung disease: A national multicenter study of 63 patients.
Fernández-Díaz C, Loricera J, Castañeda S, López-Mejías R, Ojeda-García C, Olivé A, Rodríguez-Muguruza S, Carreira PE, Pérez-Sandoval T, Retuerto M, Cervantes-Pérez EC, Flores-Robles BJ, Hernández-Cruz B, Urruticoechea A, Maíz-Alonso O, Arboleya L, Bonilla G, Hernández-Rodríguez Í, Palma D, Delgado C, Expósito-Molinero R, Ruibal-Escribano A, Álvarez-Rodríguez B, Blanco-Madrigal J, Bernal JA, Vela-Casasempere P, Rodríguez-Gómez M, Fito C, Ortiz-Sanjuán F, Narváez J, Moreno M, López-Corbeto M, Mena-Vázquez N, Aguilera-Cros C, Romero-Yuste S, Ordóñez S, Villa-Blanco I, Gonzélez-Vela MC, Mora-Cuesta V, Palmou-Fontana N, Hernández JL, González-Gay MA, Blanco R. Fernández-Díaz C, et al. Among authors: fito c. Semin Arthritis Rheum. 2018 Aug;48(1):22-27. doi: 10.1016/j.semarthrit.2017.12.012. Epub 2018 Jan 6. Semin Arthritis Rheum. 2018. PMID: 29422324
Comparative effectiveness of switching to alternative tumour necrosis factor (TNF) antagonists versus switching to rituximab in patients with rheumatoid arthritis who failed previous TNF antagonists: the MIRAR Study.
Gomez-Reino JJ, Maneiro JR, Ruiz J, Roselló R, Sanmarti R, Romero AB; MIRAR Study Group. Gomez-Reino JJ, et al. Ann Rheum Dis. 2012 Nov;71(11):1861-4. doi: 10.1136/annrheumdis-2012-201324. Epub 2012 Jun 26. Ann Rheum Dis. 2012. PMID: 22736086 Clinical Trial.
15 results